Regenxbio DMD data should have no impact on Sarepta Therapeutics (SRPT), especially at this price - BMO Capital
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $120.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), saying they ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
